GLP-1 Medications and Mental Health: What New Research Suggests About the Mind-Body Connection

Are weight loss, blood sugar, mood, and anxiety connected?

For many people, weight loss is not just about willpower or calories. Mood, anxiety, cravings, sleep, hormones, insulin resistance, inflammation, and energy levels can all overlap.

At Midwest Mind & Body Healthcare, we often see patients who feel stuck because their symptoms do not fit into one simple category. Someone may be struggling with weight gain, fatigue, low motivation, anxiety, food cravings, perimenopause symptoms, or depression, and these issues may be influencing each other.

A 2026 study published in The Lancet Psychiatry adds new data to this conversation. Researchers followed 95,490 adults with depression or anxiety in Sweden and found that semaglutide (the active ingredient in Ozempic and Wegovy) was associated with a 42% lower risk of worsening mental illness compared with non-use.

What is a GLP-1 medication?

GLP-1 receptor agonists are a class of medications that mimic glucagon-like peptide-1, a gut hormone involved in appetite regulation and blood sugar control. Common examples include:

• Semaglutide: sold as Ozempic for type 2 diabetes and Wegovy for chronic weight management
• Liraglutide: sold as Victoza (diabetes) and Saxenda (weight management)
• Tirzepatide: sold as Mounjaro (diabetes) and Zepbound (weight management); technically a dual GLP-1 and GIP agonist
• Exenatide: sold as Byetta and Bydureon
• Dulaglutide: sold as Trulicity

These medications reduce appetite, slow gastric emptying, and improve insulin response. Originally developed for diabetes, several are now approved for chronic weight management. Researchers continue to study their effects on mood, addiction, cardiovascular outcomes, and other conditions.

What did the 2026 study find about Wegovy, Ozempic, and other GLP-1 medications?

A national cohort study from Sweden, published in The Lancet Psychiatry in 2026, followed 95,490 adults diagnosed with depression, anxiety, or both who were prescribed antidiabetic medications. The cohort was 59.7% female with a mean age of 50.6 years; 22,480 individuals used a GLP-1 receptor agonist during the follow-up period. Researchers evaluated whether GLP-1 use was associated with worsening mental illness.

Semaglutide (Ozempic, Wegovy) showed the largest association

Compared with non-use, semaglutide was associated with a 42% lower risk of worsening mental illness (adjusted hazard ratio 0.58, 95% CI 0.51 to 0.65). The semaglutide-specific reductions were:

• 44% lower risk of worsening depression (aHR 0.56, 95% CI 0.44 to 0.71)
• 38% lower risk of worsening anxiety (aHR 0.62, 95% CI 0.52 to 0.73)
• 47% lower risk of worsening substance use disorder (aHR 0.53, 95% CI 0.35 to 0.80)

Liraglutide (Victoza, Saxenda) showed a smaller benefit

Liraglutide was associated with an 18% lower overall risk of worsening mental illness (aHR 0.82, 95% CI 0.76 to 0.89) and a 26% lower risk of worsening depression specifically (aHR 0.74, 95% CI 0.64 to 0.87).

Older GLP-1 medications did not show the association

Two older GLP-1 medications, exenatide (aHR 1.01, 95% CI 0.69 to 1.46) and dulaglutide (aHR 1.01, 95% CI 0.85 to 1.20), were not associated with reduced risk of worsening mental illness.

Self-harm risk was lower across the GLP-1 class

Across all GLP-1 receptor agonists combined, the medications were associated with a 44% lower risk of self-harm (aHR 0.56, 95% CI 0.34 to 0.92).

A University of Eastern Finland summary of the study reported that GLP-1 medication use, particularly semaglutide, was also associated with reduced psychiatric-related hospital care and sickness absence.

Does this mean GLP-1 medications treat depression or anxiety?

No. This is the most important part.

This study does not prove that GLP-1 medications directly treat depression or anxiety. It was an observational registry study, which means it can show an association, but it cannot prove cause and effect.

There are many possible reasons people using GLP-1 medications may have had better mental health outcomes, including:

• Weight loss
• Improved blood sugar
• Reduced food cravings
• Improved energy
• Better sleep
• Improved confidence or body image
• Lower inflammation
• Reduced alcohol use or addictive cravings
• More consistent medical follow-up

It is also possible that GLP-1 medications may have effects on brain pathways involved in reward, inflammation, and appetite regulation, but more research is needed before making strong conclusions.

Why this matters for patients

For patients, the takeaway is not "GLP-1s are antidepressants."

The better takeaway is this:

Mental health and metabolic health are deeply connected.

When someone has depression or anxiety, it can affect motivation, sleep, eating patterns, physical activity, cravings, and consistency with health goals.

When someone has insulin resistance, obesity, hormone changes, poor sleep, or chronic inflammation, those issues may also affect mood, anxiety, and energy.

That is why treating weight, mood, hormones, and lifestyle as completely separate problems may not work well for everyone.

A whole-person approach to weight loss and mental health

At Midwest Mind & Body Healthcare, we believe patients deserve care that looks at the full picture.

For some patients, medical weight loss support may improve more than the number on the scale. Patients may also notice changes in energy, cravings, confidence, sleep, and motivation.

For other patients, anxiety, depression, ADHD, trauma, perimenopause, or sleep problems may be part of what makes weight loss feel nearly impossible.

A thoughtful treatment plan may include:

• Medical weight loss options when appropriate
• Screening for depression, anxiety, ADHD, and binge eating symptoms
• Nutrition and behavior support
• Sleep and stress evaluation
• Hormone assessment when symptoms suggest perimenopause or menopause
• Medication management when clinically appropriate
• Therapy or counseling support when needed

GLP-1 medications still require careful monitoring

Even though this newer research is encouraging, GLP-1 medications are not right for everyone.

Patients should still be screened for medical history, medication risks, side effects, eating disorder history, pregnancy plans, gastrointestinal symptoms, and mental health concerns.

It is also important to monitor for mood changes, worsening anxiety, suicidal thoughts, or major changes in eating patterns. Not because this study shows increased risk, but because careful follow-up is always part of responsible medical care.

In January 2026, the FDA requested removal of suicidal ideation and behavior warning language from labels for Saxenda, Wegovy, and Zepbound. The decision followed a comprehensive review of 91 placebo-controlled trials covering more than 107,000 patients, which did not demonstrate an increased risk of suicidal behavior or ideation. Patients should still report any concerning mental health symptoms to their clinician.

The bottom line

The newer research on GLP-1 medications and mental health is promising, but it should be interpreted carefully.

GLP-1 medications should not be described as depression or anxiety treatments. However, the study supports something many clinicians and patients already recognize:

The body and mind are connected.

Weight, blood sugar, cravings, mood, sleep, hormones, and energy often overlap. For many patients, a more complete approach can be more effective than focusing on just one symptom.

At Midwest Mind & Body Healthcare, we provide care for patients who want a thoughtful, whole-person approach to mental health, medical weight loss, hormone changes, and wellness.

If your weight, mood, energy, and hormones all feel connected, you are not imagining it, and you do not have to figure it out alone.

Frequently asked questions

This content is for educational purposes only and does not replace medical advice. Treatment decisions are individualized and discussed during your visit.